Renaissance Technologies
FOLD

Renaissance Technologies’s Amicus Therapeutics FOLD Stock Holding History

Renaissance Technologies’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.1M Buy
1,872,893
+661,200
+55% +$9.48M 0.04% 540
2025
Q4 		$17.3M Sell
1,211,693
-731,478
-38% -$7.19M 0.03% 669
2025
Q3 		$15.3M Sell
1,943,171
-70,422
-3% -$501K 0.02% 866
2025
Q2 		$11.5M Buy
2,013,593
+451,600
+29% +$2.91M 0.02% 982
2025
Q1 		$12.7M Sell
1,561,993
-546,623
-26% -$5.06M 0.02% 877
2024
Q4 		$19.9M Buy
2,108,616
+1,339,316
+174% +$13.9M 0.03% 672
2024
Q3 		$8.22M Buy
769,300
+137,276
+22% +$1.5M 0.01% 1144
2024
Q2 		$6.27M Sell
632,024
-324,176
-34% -$3.33M 0.01% 1172
2024
Q1 		$11.3M Buy
956,200
+878,800
+1,135% +$11.2M 0.02% 929
2023
Q4 		$1.1M Sell
77,400
-71,000
-48% -$806K ﹤0.01% 2348
2023
Q3 		$1.8M Buy
+148,400
New +$1.91M ﹤0.01% 1930
2023
Q2 		– Sell
-389,000
Closed -$4.31M – 4040
2023
Q1 		$4.31M Buy
+389,000
New +$4.79M 0.01% 1561
2022
Q4 		– Sell
-284,800
Closed -$2.97M – 4196
2022
Q3 		$2.97M Buy
+284,800
New +$3.17M ﹤0.01% 1764
2020
Q1 		– Sell
-129,854
Closed -$1.26M – 3545
2019
Q4 		$1.26M Sell
129,854
-1,340,946
-91% -$12.3M ﹤0.01% 2524
2019
Q3 		$11.8M Buy
1,470,800
+1,217,000
+480% +$13.2M 0.01% 1284
2019
Q2 		$3.17M Buy
+253,800
New +$3.22M ﹤0.01% 2092
2016
Q4 		– Sell
-196,400
Closed -$1.45M – 3311
2016
Q3 		$1.45M Buy
+196,400
New +$1.33M ﹤0.01% 2385
2015
Q1 		– Sell
-508,700
Closed -$4.23M – 3225
2014
Q4 		$4.23M Buy
508,700
+378,300
+290% +$2.6M 0.01% 1369
2014
Q3 		$776K Buy
+130,400
New +$683K ﹤0.01% 2145
2014
Q2 		– Sell
-121,000
Closed -$250K – 2839
2014
Q1 		$250K Sell
121,000
-278,401
-70% -$696K ﹤0.01% 2565
2013
Q4 		$939K Buy
399,401
+96,801
+32% +$212K ﹤0.01% 2105
2013
Q3 		$702K Buy
302,600
+128,956
+74% +$324K ﹤0.01% 2173
2013
Q2 		$405K Buy
+173,644
New +$534K ﹤0.01% 2310

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Renaissance Technologies's FOLD Position: Q1 2026 in Review

Renaissance Technologies increased its Amicus Therapeutics (FOLD) stake by 55% in Q1 2026, buying an estimated $9.48M and bringing the position to 1,872,893 shares worth $27.1M. The position accounts for 0.04% of the portfolio, ranked #540.

Renaissance Technologies first reported a position in FOLD in Q2 2013 and has held it in 23 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Renaissance Technologies held 1,872,893 shares of Amicus Therapeutics worth $27.1M as of Q1 2026.
  • Renaissance Technologies bought 661,200 Amicus Therapeutics shares in Q1 2026, an estimated $9.48M.
  • Amicus Therapeutics made up 0.04% of Renaissance Technologies's portfolio in Q1 2026, its #540 holding.
  • Renaissance Technologies first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 23 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.